Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business HighlightsBusiness Wire • 04/29/21
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common StockBusiness Wire • 04/28/21
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common StockBusiness Wire • 04/27/21
Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With ReproxalapBenzinga • 04/27/21
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic ConjunctivitisBusiness Wire • 04/27/21
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical TrialBusiness Wire • 04/26/21
Strong Reproxalap Results Give Aldeyra A Good Balance Of Risk Versus Potential RewardSeeking Alpha • 03/16/21
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/11/21
Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business HighlightsBusiness Wire • 03/11/21
Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021Business Wire • 03/10/21
Why Earnings Season Could Be Great for Aldeyra Therapeutics (ALDX)Zacks Investment Research • 03/09/21
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business HighlightsBusiness Wire • 03/04/21
Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceBusiness Wire • 02/18/21
Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial DesignBusiness Wire • 02/04/21
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 01/20/21
Aldeyra: Reproxalap's Phase 3 Clinical Results, Expected ~75% Sales CAGR, And MoreSeeking Alpha • 01/19/21
Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech ActivityBenzinga • 01/16/21